On the role of helper lipids in lipid nanoparticle formulations of siRNA.

Onpattro, the first RNAi-based therapeutic to receive FDA approval, is enabled by a lipid nanoparticle (LNP) system that facilitates siRNA delivery into the cytoplasm of target cells (hepatocytes) following intravenous (i.v.) administration. These LNP-siRNA systems consist of four lipid components (ionizable cationic lipid, distearolyphosphatidycholine or DSPC, cholesterol, and PEG-lipid) and siRNA. The ionizable cationic lipid has been optimised for RNA encapsulation and intracellular delivery, and the PEG-lipids have been engineered to regulate LNP size and transfection potency. The roles of the other "helper" lipids, DSPC and cholesterol, remain less clear. Here we show that in empty LNP systems that do not contain siRNA, DSPC-cholesterol resides in outer layers, whereas in loaded systems a portion of the DSPC-cholesterol is internalised together with siRNA. It is concluded that the presence of internalised helper lipid is vital to the stable encapsulation of siRNA in the LNP and thus to LNP-siRNA function.

[1]  P. Cullis,et al.  Fusion-dependent formation of lipid nanoparticles containing macromolecular payloads. , 2019, Nanoscale.

[2]  P. Cullis,et al.  Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[3]  A. Bunker,et al.  Cholesterol level affects surface charge of lipid membranes in saline solution , 2014, Scientific Reports.

[4]  F. Szoka,et al.  Simple mixing device to reproducibly prepare cationic lipid-DNA complexes (lipoplexes). , 1999, BioTechniques.

[5]  S. Kato,et al.  Detailed Analysis of the Surface Area and Elasticity in the Saturated 1,2-Diacylphosphatidylcholine/Cholesterol Binary Monolayer System. , 2015, Langmuir : the ACS journal of surfaces and colloids.

[6]  G. Feigenson,et al.  Maximum solubility of cholesterol in phosphatidylcholine and phosphatidylethanolamine bilayers. , 1999, Biochimica et biophysica acta.

[7]  N C Seeman,et al.  RNA double helices generated from crystal structures of double helical dinucleoside phosphates. , 1976, Biochemical and biophysical research communications.

[8]  P. Cullis,et al.  Lipid Nanoparticle Delivery of siRNA to Osteocytes Leads to Effective Silencing of SOST and Inhibition of Sclerostin In Vivo , 2016, Molecular therapy. Nucleic acids.

[9]  D. Peter Tieleman,et al.  Lipid Nanoparticles Containing siRNA Synthesized by Microfluidic Mixing Exhibit an Electron-Dense Nanostructured Core , 2012, The journal of physical chemistry. C, Nanomaterials and interfaces.

[10]  Robert Langer,et al.  A combinatorial library of lipid-like materials for delivery of RNAi therapeutics , 2008, Nature Biotechnology.

[11]  Shigeo Matsuda,et al.  Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo** , 2012, Angewandte Chemie.

[12]  P. Cullis,et al.  Dexamethasone prodrugs as potent suppressors of the immunostimulatory effects of lipid nanoparticle formulations of nucleic acids , 2018, Journal of controlled release : official journal of the Controlled Release Society.

[13]  Rhoderick E. Brown,et al.  Phosphatidylcholine acyl unsaturation modulates the decrease in interfacial elasticity induced by cholesterol. , 1997, Biophysical journal.

[14]  Roy van der Meel,et al.  On the Formation and Morphology of Lipid Nanoparticles Containing Ionizable Cationic Lipids and siRNA. , 2018, ACS nano.

[15]  J. Heyes,et al.  Synthesis and characterization of novel poly(ethylene glycol)-lipid conjugates suitable for use in drug delivery. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[16]  E. Wachtel,et al.  Phospholipid/cholesterol model membranes: formation of cholesterol crystallites. , 2003, Biochimica et biophysica acta.

[17]  P. Cullis,et al.  Development of lipid nanoparticle formulations of siRNA for hepatocyte gene silencing following subcutaneous administration. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[18]  K. G. Rajeev,et al.  Rational design of cationic lipids for siRNA delivery , 2010, Nature Biotechnology.

[19]  P. Cullis,et al.  Design of lipid nanoparticles for in vitro and in vivo delivery of plasmid DNA. , 2017, Nanomedicine : nanotechnology, biology, and medicine.

[20]  J. Heyes,et al.  Stabilized plasmid-lipid particles containing PEG-diacylglycerols exhibit extended circulation lifetimes and tumor selective gene expression. , 2005, Biochimica et biophysica acta.

[21]  K. Cheng,et al.  Lateral distribution of cholesterol in dioleoylphosphatidylcholine lipid bilayers: cholesterol-phospholipid interactions at high cholesterol limit. , 2004, Biophysical journal.

[22]  P. Cullis,et al.  Rapid synthesis of lipid nanoparticles containing hydrophobic inorganic nanoparticles. , 2017, Nanoscale.

[23]  N. Kučerka,et al.  The Observation of Highly Ordered Domains in Membranes with Cholesterol , 2013, PloS one.

[24]  Lennart Lindfors,et al.  Successful reprogramming of cellular protein production through mRNA delivered by functionalized lipid nanoparticles , 2018, Proceedings of the National Academy of Sciences.

[25]  Nathan M Belliveau,et al.  Microfluidic Synthesis of Highly Potent Limit-size Lipid Nanoparticles for In Vivo Delivery of siRNA , 2012, Molecular therapy. Nucleic acids.

[26]  Akin Akinc,et al.  Influence of Polyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics of siRNA Lipid Nanoparticles , 2013, Molecular therapy. Nucleic acids.